title: Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia.
abstract: Schizophrenia is one of the most severe and disabling psychiatric disorders. Antipsychotic drugs offer considerable benefits in controlling symptoms and preventing relapse. The strategy for the present review of clinical trials was to ask 'What are the features of schizophrenia and the existing treatments of the illness that have implications for future clinical trials'? Six key facts were identified.First, schizophrenia is genetically 'complex'. Trials may benefit from designs including genetically related illnesses, by focussing on cross-cutting aspects of the phenotype such as psychosis or cognitive dysfunction, and by collecting information on possible moderators and mediators of treatment response.Second, schizophrenia affects multiple neurotransmitter systems. Multiple signalling pathways may need to be considered, with different time courses of response. Outcome measures from clinical trials could be collected at more frequent intervals, particularly in the early phase of response.Third, the clinical features used to define the illness are a mix of symptoms and social-occupational dysfunction, yet treatment response is often defined only by changes in symptoms. Multiple measures of functioning need to be collected at baseline and at the endpoint of trials. Consensus definitions for response, remission, relapse, recovery and recurrence need to be developed.Fourth, schizophrenia is often highly disabling. Linking treatment response in clinical trials to measures of quality-adjusted life-years will allow comparison with other medical illnesses using common metrics.Fifth, the general health and care of individuals with schizophrenia is often poor. 'Complex' interventions, which include, but are not limited to, antipsychotic medications, need to be designed and tested for the problems facing these patients.Finally, large gaps exist between clinical trials, practice guidelines and patterns of practice. Trials need to be designed to investigate widely used approaches such as antipsychotic polypharmacy, where actual practice diverges from evidence-based guidelines.
authors: Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada. honer@interchange.ubc.ca
authors: William G
authors: WG
authors: Honer
authors: Allen E
authors: AE
authors: Thornton
authors: Megan
authors: M
authors: Sherwood
authors: G William
authors: GW
authors: MacEwan
authors: Tom S
authors: TS
authors: Ehmann
authors: Richard
authors: R
authors: Williams
authors: Lili C
authors: LC
authors: Kopala
authors: Ric
authors: R
authors: Procyshyn
authors: Alasdair M
authors: AM
authors: Barr
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D017408:Guidelines as Topic; D006801:Humans; D018377:Neurotransmitter Agents / Q000502:physiology; D012107:Research Design; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D014150:Antipsychotic Agents; D018377:Neurotransmitter Agents
references: Arch Gen Psychiatry. 2001 Nov;58(11):1039-46
references: 11695950
references: Arch Gen Psychiatry. 2007 Feb;64(2):242-9
references: 17283292
references: Schizophr Bull. 2006 Apr;32(2):214-9
references: 16481659
references: Am J Psychiatry. 2006 Dec;163(12):2080-9
references: 17151158
references: Schizophr Res. 2005 Sep 1;77(1):25-34
references: 16005382
references: N Engl J Med. 2003 Oct 30;349(18):1738-49
references: 14585943
references: Stat Med. 2006 Sep 15;25(17 ):2886-910
references: 16220519
references: Am J Epidemiol. 2006 Jun 1;163(11):971-8
references: 16675535
references: N Engl J Med. 2006 Mar 23;354(12):1231-42
references: 16554525
references: Psychiatr Serv. 2006 Jan;57(1):21-3
references: 16399958
references: Acta Psychiatr Scand. 2000 Oct;102(4):303-9
references: 11089732
references: J Clin Psychopharmacol. 2005 Oct;25(5):427-34
references: 16160617
references: Lancet. 1997 May 24;349(9064):1498-504
references: 9167458
references: Br Med J. 1954 Sep 4;2(4887):560-5
references: 13182280
references: Arch Gen Psychiatry. 2004 Mar;61(3):310-7
references: 14993119
references: Arch Gen Psychiatry. 2002 Oct;59(10):877-83
references: 12365874
references: Am J Psychiatry. 2006 Apr;163(4):743-5
references: 16585455
references: Schizophr Res. 2007 May;92(1-3):90-4
references: 17321111
references: Mol Psychiatry. 2005 May;10(5):486-99
references: 15534619
references: Am J Psychiatry. 2005 Jan;162(1):130-6
references: 15625211
references: Science. 2003 Oct 31;302(5646):822-6
references: 14593167
references: Lancet. 2003 Feb 1;361(9355):417-9
references: 12573388
references: Schizophr Res. 2006 Oct;87(1-3):205-11
references: 16905294
references: Prog Neuropsychopharmacol Biol Psychiatry. 2006 Aug 30;30(6):1009-14
references: 16644082
references: J Clin Psychopharmacol. 1997 Aug;17(4):298-307
references: 9241010
references: Biol Psychiatry. 2004 Mar 15;55(6):588-93
references: 15013827
references: Br J Psychiatry. 2005 Sep;187:248-55
references: 16135862
references: Med Care. 2000 Oct;38(10):1011-21
references: 11021674
references: Eur Arch Psychiatry Clin Neurosci. 2000;250(6):274-85
references: 11153962
references: Arch Gen Psychiatry. 1967 Jan;16(1):118-26
references: 5333776
references: Schizophr Res. 2007 Jan;89(1-3):91-100
references: 17070017
references: Neuropsychopharmacology. 2003 May;28(5):995-1003
references: 12700715
references: N Engl J Med. 1999 Feb 25;340(8):603-8
references: 10029644
references: Br J Psychiatry. 1997 Dec;171:569-73
references: 9519099
references: Am J Psychiatry. 2005 Oct;162(10):1966-9
references: 16199847
references: Nature. 2002 Jul 11;418(6894):131
references: 12110869
references: Am J Psychiatry. 2002 Nov;159(11):1932-5
references: 12411232
references: Arch Gen Psychiatry. 1991 Sep;48(9):851-5
references: 1929776
references: Science. 2002 Apr 26;296(5568):692-5
references: 11976442
references: Science. 1966 May 6;152(3723):711-21
references: 17797432
references: Pharmacopsychiatry. 2004 Jan;37(1):12-7
references: 14750043
references: Bull World Health Organ. 2004 Apr;82(4):251-8
references: 15259253
references: J Clin Psychiatry. 2004 Oct;65(10):1377-88
references: 15491242
references: Schizophr Res. 2005 Nov 15;79(2-3):231-8
references: 15982856
references: NeuroRx. 2004 Apr;1(2):189-95
references: 15717019
references: Am J Psychiatry. 1957 Oct;114(4):318-27
references: 13458495
references: Pharmacogenomics J. 2007 Feb;7(1):10-28
references: 16770341
references: Am J Psychiatry. 1996 Mar;153(3):321-30
references: 8610818
references: J Psychiatr Res. 1977;13(2):91-8
references: 320322
references: Schizophr Res. 2004 Nov 1;71(1):155-65
references: 15374583
references: Am J Psychiatry. 2003 Apr;160(4):636-45
references: 12668349
references: Schizophr Bull. 2006 Oct;32(4):715-23
references: 16540702
references: J Clin Psychiatry. 2003 Jan;64(1):30-4
references: 12590620
references: J Psychopharmacol. 2005 Nov;19(6):565-6
references: 16272178
references: Br J Psychiatry. 2004 Aug;185:152-6
references: 15286067
references: Psychiatr Serv. 2003 Jan;54(1):55-9
references: 12509667
references: NeuroRx. 2004 Jul;1(3):323-30
references: 15717034
references: Schizophr Res. 2006 May;84(1):90-9
references: 16631354
references: Am J Psychiatry. 2001 Mar;158(3):440-6
references: 11229986
references: Am J Psychiatry. 2005 Mar;162(3):441-9
references: 15741458
references: Br J Psychiatry. 2005 Oct;187:366-71
references: 16199797
references: Curr Opin Psychiatry. 2005 Nov;18(6):692-9
references: 16639099
references: Arch Gen Psychiatry. 2003 Mar;60(3):231-6
references: 12622655
references: Am J Psychiatry. 2007 Feb;164(2):206-14
references: 17267781
references: Mol Psychiatry. 2004 Dec;9(12):1091-9
references: 15241432
references: Acta Psychiatr Scand. 2005 Jul;112(1):18-25
references: 15952941
references: Am J Psychiatry. 2005 Mar;162(3):631; author reply 632-3
references: 15741497
references: Neuropsychopharmacology. 2006 Oct;31(10):2318-25
references: 16823384
references: N Engl J Med. 2006 Dec 21;355(25):2631-9
references: 17182988
references: Biol Psychiatry. 2006 Jun 1;59(11):990-6
references: 16368078
references: Am J Psychiatry. 1955 Jun;111(12):930
references: 14376662
references: Am J Psychiatry. 2003 Dec;160(12):2234-6
references: 14638597
references: Am J Psychiatry. 2001 Apr;158(4):518-26
references: 11282684
references: N Engl J Med. 2002 Jan 3;346(1):16-22
references: 11777998
references: Arch Gen Psychiatry. 2005 Sep;62(9):961-70
references: 16143728
references: N Engl J Med. 2005 Sep 22;353(12 ):1209-23
references: 16172203
references: J Clin Psychiatry. 2004 Dec;65(12):1597-600
references: 15641863
references: Am J Psychiatry. 2005 Dec;162(12):2393-4; author reply 2394
references: 16330612
references: Lancet. 1999 Jul 10;354(9173):111-5
references: 10408486
references: J Am Med Assoc. 1954 May 1;155(1):18-21
references: 13151880
references: Int J Neuropsychopharmacol. 2004 Jun;7(2):113-6
references: 14984629
references: Neuropsychopharmacology. 2007 Sep;32(9):1903-10
references: 17287825
references: Nat Rev Drug Discov. 2006 Feb;5(2):133-46
references: 16518380
references: BMC Psychiatry. 2005 May 27;5:26
references: 15921508
references: Arch Gen Psychiatry. 2005 Dec;62(12):1305-12
references: 16330718
references: Int J Neuropsychopharmacol. 2006 Jun;9(3):357-66
references: 16316478
references: Psychiatr Serv. 2005 Mar;56(3):283-91
references: 15746502
references: Psychiatr Serv. 2006 Jan;57(1):127-9
references: 16399974
references: Pharmacoeconomics. 1998 May;13(5 Pt 2):575-88
references: 17165324
references: Schizophr Res. 2006 Sep;86(1-3):138-46
references: 16793238
references: N Engl J Med. 2006 Feb 2;354(5):472-82
references: 16452559
references: Schizophr Res. 1988 Jan-Feb;1(1):3-18
references: 3154503
references: Trends Genet. 2005 Sep;21(9):518-25
references: 16009449
references: Br J Psychiatry. 1998 Oct;173:325-9
references: 9926037
references: Biol Psychiatry. 2005 Jun 15;57(12):1543-9
references: 15953491
references: Prog Neuropsychopharmacol Biol Psychiatry. 1994 Jan;18(1):129-37
references: 7509495
references: Schizophr Res. 2004 Nov 1;71(1):83-95
references: 15374576
references: Br J Psychiatry. 2006 Feb;188:122-7
references: 16449697
references: N Engl J Med. 2006 Mar 23;354(12):1243-52
references: 16554526
references: Arch Gen Psychiatry. 2006 Apr;63(4):366-73
references: 16585465
references: Eur Neuropsychopharmacol. 2005 Aug;15(4):399-409
references: 15925493
references: Nat Rev Neurosci. 2005 Apr;6(4):312-24
references: 15803162
references: Arch Gen Psychiatry. 2006 Oct;63(10):1079-87
references: 17015810
references: Biol Psychiatry. 1999 Jul 1;46(1):56-72
references: 10394474
references: J Psychopharmacol. 2003 Jun;17 (2):223-9
references: 12870571
references: Schizophr Res. 2006 Sep;86(1-3):309-20
references: 16806839
references: BMC Med. 2004 Apr 28;2:13
references: 15115547
references: Int Clin Psychopharmacol. 2006 Mar;21 Suppl 2:S1-10
references: 16601507
references: Am J Psychiatry. 2004 Apr;161(4):700-6
references: 15056517
references: Nat Med. 2006 Jul;12(7):824-8
references: 16767099
references: Schizophr Bull. 1998;24(1):11-20; discussion 20-32
references: 9502543
references: Acta Psychiatr Scand. 2002 Nov;106(5):323-30
references: 12366465
references: Am J Hum Genet. 1990 Feb;46(2):222-8
references: 2301392
references: J Clin Psychiatry. 2007 Mar;68(3):352-60
references: 17388703
references: Schizophr Res. 2005 Dec 1;80(1):19-32
references: 16137860
references: Pharmacoeconomics. 2000 Apr;17 (4):383-9
references: 10947493
references: Nature. 2005 Sep 22;437(7058):491-3
references: 16177777
references: Am J Psychiatry. 2003 Mar;160(3):477-82
references: 12611828
references: Am J Psychiatry. 2006 Apr;163(4):600-10
references: 16585434
references: N Engl J Med. 2006 Feb 2;354(5):518-20
references: 16452565
references: Int J Neuropsychopharmacol. 2004 Jun;7(2):133-42
references: 14741059
references: J Clin Psychiatry. 2005 Jan;66(1):63-72
references: 15669890
references: Arch Gen Psychiatry. 2003 May;60(5):458-64
references: 12742866
references: Br J Psychiatry. 2005 Sep;187:243-7
references: 16135861
references: J Clin Psychiatry. 2005 Feb;66(2):183-94; quiz 147, 273-4
references: 15705003
references: Arch Gen Psychiatry. 2003 May;60(5):466-72
references: 12742867
references: Schizophr Bull. 2005 Jan;31(1):5-19
references: 15888422
references: NeuroRx. 2004 Apr;1(2):182-8
references: 15717018
references: Schizophr Bull. 2006 Jan;32(1):9-16
references: 16319375
references: JAMA. 2003 Jun 18;289(23):3152-60
references: 12813121
references: Pharmacopsychiatry. 2004 Jul;37(4):175-9
references: 15467975
references: N Engl J Med. 2006 Apr 20;354(16):1667-9
references: 16625007
references: J Clin Psychiatry. 2006 Dec;67(12):1912-9
references: 17194269
references: Arch Gen Psychiatry. 2003 Dec;60(12):1228-35
references: 14662555
references: N Engl J Med. 2006 Mar 23;354(12):1305-7
references: 16554533
references: Biol Psychiatry. 2005 May 15;57(10):1117-27
references: 15866551
references: Aust N Z J Psychiatry. 2004 Apr;38(4):240-5
references: 15038803
references: Br J Psychiatry. 2003 Feb;182:117-22
references: 12562738
references: Am J Psychiatry. 2003 Aug;160(8):1514-6
references: 12900316
references: BMJ. 1998 Oct 31;317(7167):1181-4
references: 9794850